Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.40 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4021282 | 0.84 | NPC1 (0.39) | GRM2SLC9A1SLC9A2MAPK1RAB9A | |
| SCHEMBL4013457 | 0.78 | TEK (0.52) | GPR142RAB9ANPC1PKMALDH1A1 | |
| SCHEMBL9906354 | 0.77 | ALDH1A1 (0.43) | GPR142ALDH1A1 | |
| SCHEMBL4016845 | 0.76 | BRAF (0.51) | MAPK14 | |
| SCHEMBL3642234 | 0.76 | MIF (0.51) | GPR142 | |
| SCHEMBL4017103 | 0.76 | MAPK14 (0.45) | MAPK14RAB9ANPC1PKM | |
| SCHEMBL13843757 | 0.75 | PTGDR2 (0.46) | RAB9ANPC1PKMALDH1A1 | |
| SCHEMBL4033327 | 0.74 | BRAF (0.45) | MAPK14 | |
| SCHEMBL4017503 | 0.74 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL4016376 | 0.74 | TEK (0.52) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531560-B2 | Anti-cytokine heterocyclic compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20060100204-A1 | Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100204-A1 | Heterocyclic-substituted benzamide derivatives, e.g., benzyl [2-(4-{1-[5-(5-tert-Butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-2-methyl-phenyl]-1H-1,2,3-triazol-4-yl}-2-phenyl-2H-pyrazol-3-yl)-ethyl]-carbamate; inhibit production of cytokines; useful for treating chronic inflammatory disease. | NFKBIA, CHUK, IL1B | GRM2 2954/4885MAPK14 515/4885SLC9A1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.